Erschienen in:
01.10.2013 | Adis Drug Clinical Q&A
Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies
verfasst von:
Katherine A. Lyseng-Williamson, Sean T. Duggan, Gillian M. Keating
Erschienen in:
BioDrugs
|
Ausgabe 5/2013
Einloggen, um Zugang zu erhalten
Abstract
Pegylated liposomal doxorubicin (Caelyx® [EU], Doxil® [USA]) represents an improved formulation of conventional doxorubicin, with reduced cardiotoxicity and an improved pharmacokinetic profile. As shown by evidence from clinical trials, intravenous pegylated liposomal doxorubicin is a useful option in the treatment of various malignancies, including metastatic breast cancer, ovarian cancer, multiple myeloma, and AIDS-related Kaposi sarcoma. It has a favourable safety profile relative to conventional doxorubicin and other available chemotherapy agents.